Milrinone
Milrinone is a phosphodiesterase inhibitor, and is used for less than 48 hours, in coronary care or intensive care settings, for severe heart failure that is refractory to other treatments. Significant adverse effects include supraventricular and ventricular arrhythmias (continuous ECG monitoring is required), angina, and hypotension. It can increase mortality in patients with an acute exacerbation of chronic heart failure. Milrinone is renally excreted, and doses need to be halved in patients with severe impairment. Avoid mixing with frusemide injections, as precipitation occurs.
Comments
Post a Comment